Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management

Bibliography

• Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307(5):491-7
   PubMed Web of Science ®Google Scholar
• Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obesity Rev 2001;2(4):219-29
   PubMedGoogle Scholar
• National Heart, Lung, and Blood Institute. The clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health, Bethesda; 1998; NIH Publication No. 98-4083
   Google Scholar
• Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110(18):2952-67
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2013. Diabetes Care 2013;36(Suppl 1):S11-66
   PubMed Web of Science ®Google Scholar
• Reaven GM. Importance of identifying the overweight patient who will benefit the most by losing weight. Ann Intern Med 2003;138(5):420-3
   PubMed Web of Science ®Google Scholar
• Schmier JK, Jones ML, Halpern MT. Cost of obesity in the workplace. Scand J Work Environ Health 2006;32(1):5-11
   PubMed Web of Science ®Google Scholar
• Belviq® [package insert]. Arena Pharmaceuticals, Zofingen, Switzerland
   Google Scholar
• Qsymia® [package insert]. VIVUS, Inc., Mountain View, CA
   Google Scholar
• Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012;307(1):56-65
   PubMed Web of Science ®Google Scholar
• Bal BS, Finelli FC, Shope TR, Koch TR. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol 2012;8(9):544-56
   PubMed Web of Science ®Google Scholar
• Sjöström L, Gummesson A, Sjöström CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009;10(7):653-62
   PubMed Web of Science ®Google Scholar
• Keidar A. Bariatric surgery for type 2 diabetes reversal: the risks. Diabetes Care 2011;34(Suppl 2):S361-6
   PubMedGoogle Scholar
• Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation 2012;125(13):1695-703
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-61
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W, et al. SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363(10):905-17
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363(3):245-56
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96(10):3067-77
   PubMed Web of Science ®Google Scholar
• Makowski CT, Gwinn KM, Hurren KM. Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obesity Facts 2011;4(6):489-94
   PubMed Web of Science ®Google Scholar
• Topamax® [package insert]. Ortho-McNeil Neurologics, Inc., Titusville, NJ
   Google Scholar
• Rueger R, Garvey WT, Morelos S, Troupin B. Glycemic improvement and weight loss with low-dose, controlled-release phentermine/topiramate. Abstract 181580. American Association of Diabetes Educators 37th Annual Meeting (AADE); 4 – 7 August 2010; San Antonio, Texas, USA
   Google Scholar
• Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 2012;35(11):1529-39
   PubMed Web of Science ®Google Scholar
• Chowdhuri S. Continuous positive airway pressure for the treatment of sleep apnea. Otolaryngol Clin North Am 2007;40(4):807-27
   PubMed Web of Science ®Google Scholar
• Brownell K. The LEARN program for weight management. The Life Style Co, Dallas; 2000
   Google Scholar
• Jordan J, Astrup A, Day WW. Effects of phentermine and extended-release topiramate alone and in combination on cardiovascular risk factors. Poster 697. 48th Annual Meeting of the European Association for the Study of Diabetes; 1 – 5 October 2012; Berlin, Germany
   Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012;20(2):330-42
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9774):1341-52
   PubMed Web of Science ®Google Scholar
• Garvey WT, Peterson CA, Troupin B. Weight loss with low-dose, controlled-release phentermine/topiramate therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus [abstract T5:P102]. 18th European Congress of Obesity; 25 – 28 May 2011; Istanbul, Turkey
   Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95(2):297-308
   PubMed Web of Science ®Google Scholar
• United States FDA. Slides for the February 22, 2012 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm293903.htm [Last accessed 8 January 2013]
   Google Scholar
• Green MW, Seeger JD, Peterson C, Bhattacharyya A. Utilization of topiramate during pregnancy and risk of birth defects. Headache 2012;52(7):1070-84
   PubMed Web of Science ®Google Scholar
• Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocrine Pract 2012;18(5):642-8
   PubMed Web of Science ®Google Scholar
• Hofsø D, Jenssen T, Bollerslev J, et al. Beta cell function after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol 2011;164(2):231-8
   PubMed Web of Science ®Google Scholar
• Look AHEAD Research Group. Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30(6):1374-83
   PubMed Web of Science ®Google Scholar
• Look AHEAD Research Group. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170(17):1566-75
   PubMed Web of Science ®Google Scholar
• Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353(20):2111-20
   PubMed Web of Science ®Google Scholar
• Davidson MH, Tonstad S, Oparil S, et al. Changes in cardiovascular risk associated with phentermine and topiramate extended release in participants with comorbidities and a body mass index ≥ 27 kg/m2. Am J Cardiol 2013; published on-line January 29, 2013; doi: 10.1016/j.amjcard.2012.12.038
   Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120(16):1640-5
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl 1):S67-74
   PubMed Web of Science ®Google Scholar
• Liao Y, Kwon S, Shaughnessy S, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004;27(4):978-83
   PubMed Web of Science ®Google Scholar
• Blüher M. Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes 2012;19(5):341-6
   PubMed Web of Science ®Google Scholar
• Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008;168(15):1617-24
   PubMed Web of Science ®Google Scholar
• Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004;109(6):706-13
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366(9497):1640-9
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31(3):596-615
   PubMed Web of Science ®Google Scholar
• Benotti PN, Still CD, Wood GC, et al. Preoperative weight loss before bariatric surgery. Arch Surg 2009;144(12):1150-5
   PubMed Web of Science ®Google Scholar
• Heber D, Greenway FL, Kaplan LM, et al. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010;95(11):4823-43
   PubMed Web of Science ®Google Scholar
• Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2007;66(4):433-9
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005;90(12):6364-9
   PubMed Web of Science ®Google Scholar
• Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51(1):121-9
   PubMed Web of Science ®Google Scholar
• Tuomilehto HP, Seppä JM, Partinen MM, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med 2009;179(4):320-7
   PubMed Web of Science ®Google Scholar
• Church T, Troupin B. Improvements in quality of life by magnitude of weight loss in obese and overweight subjects. Abstract 1623811. 36th Annual Society of General Internal Medicine; 24 – 27 April 2013; Denver, Colorado
   Google Scholar